LYSAKER, NORWAY--(Marketwire - February 12, 2008) -
Pronova BioPharma continued strong and profitable growth in Q4 and throughout 2007, with demand for Omacor/Lovaza growing by 61 per cent compared to Q4 2006. EBITDA in Q4 reached NOK 122.4 million (NOK 106.6 million). EBITDA for 2007 was NOK 503.3 million (NOK 271.4 million). Revenues in the quarter were up 32.3 per cent to NOK 269.4 million (NOK 203.6 million), driven by strong US growth. Revenues for the year were NOK 1 014.4 million (NOK 669.4 million).
